MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).

There has been a lot of talk about drugs targeting both PD-1 and VEGF stealing the crown held by MSD's Keytruda in cancer immunotherapy. Now, the company has made a move to try to make sure it isn't ...

Cadence is a placebo-controlled, randomised, double-blind trial assessing Winrevair’s safety and efficacy in CpcPH patients.

Healthcare company MSD Ireland has invested over €1 billion in a new site in Dunboyne in Co Meath as well as significantly expanding its existing site in Carlow. The investment has led to the creation ...

MSD Partners has raised about $1.1 billion for a fund dedicated to bets on structured credit secured by real estate, beating an initial target of $750 million. The MSD Real Estate Credit Opportunity ...